title: Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study.
abstract: The impact of sildenafil on pulmonary arterial hypertension (PAH) in Chinese patients has been less investigated. A prospective, open-label, uncontrolled and multicenter study, therefore, was carried out to address this issue. Ninety patients with multicause-induced PAH received oral sildenafil (75 mg/day) for 12 weeks. The 6-minute walk test (SMWT) and cardiac catheterization were performed at the beginning and the end of the 12 weeks. The primary endpoint was the changes in exercise capacity assessed by the SMWT; the secondary endpoint included assessment of functional class, evaluation of cardiopulmonary hemodynamics, and clinical worsening. Drug safety and tolerability were also examined. The results showed that there was a significant improvement in SMWT distances (342 ± 93 m vs 403 ± 88 m, P < .0001), Borg dyspnea score (2.9 ± 2.6 vs 2.4 ± 2.0, P = .0046), World Health Organization functional class, and cardiopulmonary hemodynamics (mean pulmonary artery pressure, P < .0001; cardiac index, P < .0001; pulmonary vascular resistance, P < .0001) after 12 weeks of oral sidenafil therapy. Almost all enrolled patients did not experience significant clinical worsening. This study confirms and extends the findings of previous studies relating to effects of sildenafil on PAH, suggesting that oral sildenafil is safe and effective for the treatment of adult patients with PAH in the Chinese population.
authors.affiliation: Center for Diagnosis and Management of Pulmonary Vascular Diseases, Department of Cardiology, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
authors.forename: Chang-Ming
authors.initials: CM
authors.lastname: Xiong
authors.forename: Xian-Ling
authors.initials: XL
authors.lastname: Lu
authors.forename: Guang-Liang
authors.initials: GL
authors.lastname: Shan
authors.forename: Bing-Xiang
authors.initials: BX
authors.lastname: Wu
authors.forename: Xian-Yang
authors.initials: XY
authors.lastname: Zhu
authors.forename: Guang-Hua
authors.initials: GH
authors.lastname: Wu
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Zeng
authors.forename: Tao
authors.initials: T
authors.lastname: Guo
authors.forename: Zhi-Hong
authors.initials: ZH
authors.lastname: Liu
authors.forename: Xin-Hai
authors.initials: XH
authors.lastname: Ni
authors.forename: Xian-Sheng
authors.initials: XS
authors.lastname: Cheng
authors.forename: Qing
authors.initials: Q
authors.lastname: Gu
authors.forename: Zhi-Hui
authors.initials: ZH
authors.lastname: Zhao
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Tian
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Li
authors.forename: Duan-Zhen
authors.initials: DZ
authors.lastname: Zhang
authors.forename: Cheng
authors.initials: C
authors.lastname: Zhang
authors.forename: Meng-Tao
authors.initials: MT
authors.lastname: Li
authors.forename: Hong-Min
authors.initials: HM
authors.lastname: Liu
authors.forename: Ya-Juan
authors.initials: YJ
authors.lastname: Guo
authors.forename: Jie-Yan
authors.initials: JY
authors.lastname: Shen
authors.forename: Wei-Jun
authors.initials: WJ
authors.lastname: Zhang
authors.forename: Shuang
authors.initials: S
authors.lastname: Liu
authors.forename: Da-Xin
authors.initials: DX
authors.lastname: Zhou
authors.forename: Chun-De
authors.initials: CD
authors.lastname: Bao
authors.forename: Shi-An
authors.initials: SA
authors.lastname: Huang
authors.forename: Jian-Ying
authors.initials: JY
authors.lastname: Chen
authors.forename: Wei-Feng
authors.initials: WF
authors.lastname: Wu
authors.forename: Kai
authors.initials: K
authors.lastname: Huang
authors.forename: Chang-ling
authors.initials: CL
authors.lastname: Li
authors.forename: Li-Hua
authors.initials: LH
authors.lastname: Wang
authors.forename: Bei
authors.initials: B
authors.lastname: He
authors.forename: Jian-Guo
authors.initials: JG
authors.lastname: He
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Li
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002681:China / Q000453:epidemiology; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate